Preclinical studies have shown that blocking IL‐10 or CSF1R in aged melanoma‐bearing mice can partially restore responsiveness to checkpoint blockade, underscoring the central role of myeloid dysfunction in therapeutic resistance [68]. This evidence concerns the gene IL10 and melanoma.